Phosphorus dioxide and carbon dioxide pyridine derivatives, such as quinolone hydroxyl inhibitors； pharmacological synthesis； in vitro inhibition； and for the treatment or prevention of liver fibrosis, diabetes mellitus or metabolic Sindrome transport Liver fibrosis.
BENNETT, BRYDON L.,ELSNER, JAN,ERDMAN, PAUL,HILGRAF, ROBERT,LEBRUN, LAURIE ANN,MOGHADDAM, MEHRAN F.,NAGY, MARK A.,NORRIS, STEPHEN,PAISNER, DAVID A.,SLOSS, MARIANNE,ROMANOV, WILLIAM J.,SATOH, YOSHITAKA,MCCCARRICK, MEG
申请号：
CL2013003025
公开号：
CL2013003025A1
申请日:
2013.10.18
申请国别(地区):
CL
年份:
2014
代理人:
摘要：
Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.COMPUESTOS DERIVADOS DE PIRIMIDINAS DE DIAMINOCARBOXAMIDA Y DIAMINOCARBONITRILO, COMO INHIBIDORES DE QUINASA JNK； COMPOSICION FARMACEUTICA； METODO DE INHIBICION IN VITRO； Y SU USO EN EL TRATAMIENTO O PREVENCION DE TRASTORNOS FIBROTICOS DEL HIGADO, DIABETES O SINDROME METABOLICO CONDUCIENDO A TRASTORNOS FIBROTICOS DEL HIGADO.
